Clinical trial · Interventional
Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer
Pre-Surgical Detection of Colorectal Carcinomas Using 123Iodine-Labeled cT84.66 Diabody Antibody Fragments to Carcinoembryonic Antigen (CEA)
NCT00647153CI-TRIAL-00030177completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as immunoscintigraphy, using a radiolabeled monoclonal antibody may help find and diagnose colorectal cancer. PURPOSE: This clinical trial is studying how well immunoscintigraphy using a radiolabeled monoclonal antibody works in finding tumor cells in patients with colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| iodine I 123 anti-CEA recombinant diabody T84.66 | Radiation | — | UNRESOLVED |
| pharmacological study | Other | — | UNRESOLVED |
| single photon emission computed tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Radiation: iodine I 123 anti-CEA recombinant diabody T84.66
- interventionNames
- Other: pharmacological study
- Procedure: single photon emission computed tomography
- Radiation: iodine I 123 anti-CEA recombinant diabody T84.66
Primary outcomes (1)
- measure
- Tumor targeting properties of iodine I 123 anti-CEA recombinant diabody T84.66
- timeFrame
- Day 2 post infusion
Secondary outcomes (3)
- measure
- Clinical pharmacokinetics of iodine I 123 anti-CEA recombinant diabody T84.66
- timeFrame
- Day 2 post infusion
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed colorectal cancer * Stage I-IV disease PATIENT CHARACTERISTICS: * Serum creatinine \< 2.0 mg/dL * Total bilirubin \< 2.0 mg/dL * Hemoglobin \> 9.0 g/dL * cT84.66 antibody negative (if previously treated with mouse or chimeric immunoglobulins) * Not pregnant * No condition that, in the opinion of the investigator, would preclude study compliance * No known allergy to iodine * No known history of HIV, hepatitis B, or hepatitis C PRIOR CONCURRENT THERAPY: * No concurrent steroids
References
Publications (0)
Data not yet available
No reference posted for this study.